Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.

Employees - 7, CEO - Mr. Alexander Pickett, Sector - Healthcare, Country - VG, Market Cap - 6.76M

Altman ZScore(max is 10): -217.79, Piotroski Score(max is 10): 3, Working Capital: $1813000, Total Assets: $2706000, Retained Earnings: $-242334000, EBIT: -78086000, Total Liabilities: $2011000, Revenue: $0

AryaFin Target Price - $0.24 - Current Price $6.03 - Analyst Target Price $140.00